nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Back Matter
|
|
|
|
141 |
5 |
p. I |
artikel |
2 |
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
|
Falchi, Lorenzo |
|
|
141 |
5 |
p. 467-480 |
artikel |
3 |
Composite ALK-negative anaplastic large-cell lymphoma and mantle cell lymphoma
|
Pina-Oviedo, Sergio |
|
|
141 |
5 |
p. 556 |
artikel |
4 |
DDX41: the poster child for familial MDS/AML grows up
|
Truong, Peter |
|
|
141 |
5 |
p. 447-449 |
artikel |
5 |
Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL
|
Hengeveld, Paul J. |
|
|
141 |
5 |
p. 519-528 |
artikel |
6 |
Editorial Board
|
|
|
|
141 |
5 |
p. vi |
artikel |
7 |
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
|
Etra, Aaron |
|
|
141 |
5 |
p. 481-489 |
artikel |
8 |
Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities
|
Cappelli, Luca Vincenzo |
|
|
141 |
5 |
p. 503-518 |
artikel |
9 |
ERGonomics for EVI1 acute myeloid leukemia
|
Lopez, Cécile K. |
|
|
141 |
5 |
p. 441-443 |
artikel |
10 |
EVI1 drives leukemogenesis through aberrant ERG activation
|
Schmoellerl, Johannes |
|
|
141 |
5 |
p. 453-466 |
artikel |
11 |
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
|
Makishima, Hideki |
|
|
141 |
5 |
p. 534-549 |
artikel |
12 |
Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype
|
Khodadoust, Michael |
|
|
141 |
5 |
p. 555 |
artikel |
13 |
Looking for a needle in the haystack of CLL
|
Ferrero, Simone |
|
|
141 |
5 |
p. 445-447 |
artikel |
14 |
Masthead Subscription
|
|
|
|
141 |
5 |
p. i |
artikel |
15 |
Neutrophil-specific depletion of gasdermin D does not protect against murine sepsis
|
Liu, Fei |
|
|
141 |
5 |
p. 550-554 |
artikel |
16 |
Newer insights on how to TEC down T-ALL
|
Iyer, Swaminathan P. |
|
|
141 |
5 |
p. 444-445 |
artikel |
17 |
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
|
Svaton, Michael |
|
|
141 |
5 |
p. 529-533 |
artikel |
18 |
Progress in risk-adapted acute GVHD therapy
|
Pidala, Joseph |
|
|
141 |
5 |
p. 443-444 |
artikel |
19 |
Table of Contents
|
|
|
|
141 |
5 |
p. iii-iv |
artikel |
20 |
The complicated role of neutrophil gasdermin D in sepsis
|
Kolaczkowska, Elzbieta |
|
|
141 |
5 |
p. 449-451 |
artikel |
21 |
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
|
Lecomte, Sara |
|
|
141 |
5 |
p. 490-502 |
artikel |